000			02005 a2200553 4500
005			20250514005719.0
264		0	_c20010920
008			200109s 0 0 eng d
022			_a0020-7136
024	7		_a10.1002/ijc.1406 _2doi
040			_aNLM _beng _cNLM
100	1		_aJurianz, K
245	0	0	_aK562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. _h[electronic resource]
260			_bInternational journal of cancer _cSep 2001
300			_a848-54 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntigens, CD _ximmunology
650	0	4	_aCD55 Antigens _ximmunology
650	0	4	_aCD59 Antigens _ximmunology
650	0	4	_aCell Membrane _xmetabolism
650	0	4	_aComplement Activation
650	0	4	_aComplement System Proteins _ximmunology
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aErythrocytes _xmetabolism
650	0	4	_aFlow Cytometry
650	0	4	_aHumans
650	0	4	_aK562 Cells
650	0	4	_aLeukemia, Erythroblastic, Acute _ximmunology
650	0	4	_aMembrane Cofactor Protein
650	0	4	_aMembrane Glycoproteins _ximmunology
650	0	4	_aNaphthalenes _xpharmacology
650	0	4	_aNeutrophils _xmetabolism
650	0	4	_aPlant Proteins _xpharmacology
650	0	4	_aProtein Kinase C _xmetabolism
650	0	4	_aSignal Transduction
650	0	4	_aTetradecanoylphorbol Acetate _xpharmacology
650	0	4	_aTrypsin Inhibitors
650	0	4	_aTumor Necrosis Factor-alpha _xpharmacology
650	0	4	_aalpha-Amylases _xantagonists & inhibitors
700	1		_aZiegler, S
700	1		_aDonin, N
700	1		_aReiter, Y
700	1		_aFishelson, Z
700	1		_aKirschfink, M
773	0		_tInternational journal of cancer _gvol. 93 _gno. 6 _gp. 848-54
856	4	0	_uhttps://doi.org/10.1002/ijc.1406 _zAvailable from publisher's website
999			_c11443451 _d11443451